


REMARKS

The Examiner has objected to the specification as lacking Sequence Identification Numbers and a sequence listing. Applicant has amended the specification to include Sequence Identification Numbers and has provided a corresponding sequence listing.

Claims 1-31, 38, 43-45, 47, 54, 55, 57, 63-70, 72, 83, 87, 94, 98, 105, 117-119, 126, 128-130, and 132 have been objected or rejected by the Examiner. These claims have been canceled. Remaining claims 39-42, 46, 48-53, 56, 58-62, 71, 75, 77, 78, 82, 86, 88-93, 97, 99-104, 108, 110-114, 116, 120-125, 127, 131, 133 and 134 are allowed. Applicant submits that the application and claims are in condition for allowance and request favorable reconsideration of the application.

Respectfully submitted,



Michael M. Conger
Attorney for Applicants
Registration No. 43,562

Date: April 19, 2006
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-2474
Facsimile: 919-483-7988